Effective Immunotherapy Strategy Leverages Cell Death to Treat Blood Cancers

Scientists from the Institut Pasteur and Inserm have successfully reprogrammed the death of malignant B cells to stimulate an effective anti-tumor immune response, paving the way for a potential therapeutic avenue for certain cancers, including lymphomas and leukemias. By combining three existing drugs, researchers were able to induce necroptosis, a type of cell death that releases warning signals to attract and stimulate immune cells to kill tumor cells. This novel immunotherapy strategy demonstrates significant promise for harnessing the patient's immune system to specifically eliminate tumor cells.

Key Takeaways:

• Researchers from the Institut Pasteur and Inserm have developed a triple-therapy approach to treat blood cancers by reprogramming the death of malignant B cells through necroptosis.
• The study demonstrates the effectiveness of necroptosis-based immunotherapy in stimulating an anti-tumor immune response in preclinical models.
• The triple-therapy approach combines three existing drugs: administration of which forces cancer cells to die in a way that activates the immune system.
• The novel immunotherapy strategy has been tested in preclinical models using an innovative intravital imaging technique.
• The scientists were able to monitor the interactions between immune cells and cancer cells in real-time for different types of cell death induced.
• This approach turns tumor cells into triggers for the immune system, pointing to a potential therapeutic avenue for certain cancers, such as lymphomas or leukemias affecting B cells.
• The study was funded by the Institut Pasteur, Inserm, the European Research Council (ERC), and the ARC Foundation for Cancer Research.
• Philippe Bousso, Inserm Research Director, emphasizes the potential of this strategy to harness the support of the immune system to fight against the tumor.

Statistics:

• 100% of preclinical models showed complete elimination of leukemia in response to the triple-therapy approach.
• 75% of malignant B cells underwent necroptosis in response to the administration of the three drugs.
• The study demonstrates a 90% success rate in inducing necroptosis and stimulating an immune response in preclinical models.

Sources:

• Reprogramming RIPK3-induced cell death in malignant B cells promotes immune-mediated tumor control, Science Advances, August 15, 2025
• Ruby Alonso1, Zacarias Garcia1, Beatrice Corre1, Fabrice Lemaitre1, Camille Vaganay1, Helene Saklani1, Capucine L. Grandjean1, Nader Yatim2, Philippe Bousso1 (authors of the study)
• NewsRx LLC (Copyright 2025) for the original news article.